Scholars@Duke
Herbert Kim Lyerly

Herbert Kim Lyerly

George Barth Geller Distinguished Professor of Immunology
Surgery, Surgical Sciences
lyerl001@mc.duke.edu
Box 2606 Med Ctr, Durham, NC 27710
203 Research Drive, Rm 433B, Box 2606, Durham, NC 27710

Scholarly Works - Other

FIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. <b>A,</b> WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; <i>n</i> = 5/group) and ser ... Full text Cite

Figure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Validating mutant GFP and Luc activity in Adenovirus vaccines</p> ... Full text Cite

FIGURE 7 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Summary of tumor behavior in differentially tolerant animal models. <b>A,</b> Xenoantigen-bearing tumor cells implanted orthotopically into immune-deficient mice typically grow and metastasize as expected and can be easily obse ... Full text Cite

FIGURE 6 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice reveal unappreciated metastatic dynamics independent of the primary tumor. <b>A,</b> Tumor growth of triple transgenic (3 ×) B16-F10 cells (10<sup>5</sup>) after subcutaneous implantation into the flank ... Full text Cite

FIGURE 5 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Tumor cells expressing GFP, rtTA, and Luciferase successfully engraft in NoGlow mice. <b>A,</b> Diagram of triple-transgenic (3 ×) E0771 cells. GFP and rtTA are constitutively expressed and Luc is induced with the addition of d ... Full text Cite

FIGURE 6 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice reveal unappreciated metastatic dynamics independent of the primary tumor. <b>A,</b> Tumor growth of triple transgenic (3 ×) B16-F10 cells (10<sup>5</sup>) after subcutaneous implantation into the flank ... Full text Cite

Figure S4 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Confirming triple-transgenic GFP rtTA-Luc construct in E0771 cells</p> ... Full text Cite

FIGURE 4 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice reveal the impact of sex and tissue distribution on immune tolerance. <b>A,</b> Male WT (<i>n</i> = 3), CAG Luc-GFP (<i>n</i> = 3), and NoGlow+ (<i>n</i> = 6) or NoGlow− (<i&gt ... Full text Cite

Figure S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Additional E0771 tumor growth in WT, GH, and CAG Luc-GFP mice; MMTV CAG HER2 Ad-HER2 vaccination T cell responses.</p> ... Full text Cite

FIGURE 7 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Summary of tumor behavior in differentially tolerant animal models. <b>A,</b> Xenoantigen-bearing tumor cells implanted orthotopically into immune-deficient mice typically grow and metastasize as expected and can be easily obse ... Full text Cite

Data from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <div>Abstract<p>The ability to temporally regulate gene expression and track labeled cells makes animal models powerful biomedical tools. However, sudden expression of xenobiotic genes [e.g., GFP, luciferase (Luc), or rtTA3] can trigger ... Full text Cite

Data from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <div>Abstract<p>The ability to temporally regulate gene expression and track labeled cells makes animal models powerful biomedical tools. However, sudden expression of xenobiotic genes [e.g., GFP, luciferase (Luc), or rtTA3] can trigger ... Full text Cite

FIGURE 1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Tolerance to foreign antigens is animal model specific. <b>A</b> and <b>B,</b> Mice expressing GFP and Luc in the pituitary (GH; <i>n</i> = 5), full-body GFP, and Luc (CAG Luc-GFP; <i>n</i> = ... Full text Cite

FIGURE 3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice express eGFP and Luciferase without background fluorescence and bioluminescence. <b>A,</b> Diagram of the NoGlow construct. LoxP-flanked stop site prevents expression of the NoGlow construct in the absence of Cre re ... Full text Cite

FIGURE 4 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice reveal the impact of sex and tissue distribution on immune tolerance. <b>A,</b> Male WT (<i>n</i> = 3), CAG Luc-GFP (<i>n</i> = 3), and NoGlow+ (<i>n</i> = 6) or NoGlow− (<i&gt ... Full text Cite

FIGURE 5 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Tumor cells expressing GFP, rtTA, and Luciferase successfully engraft in NoGlow mice. <b>A,</b> Diagram of triple-transgenic (3 ×) E0771 cells. GFP and rtTA are constitutively expressed and Luc is induced with the addition of d ... Full text Cite

Figure S4 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Confirming triple-transgenic GFP rtTA-Luc construct in E0771 cells</p> ... Full text Cite

FIGURE 3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice express eGFP and Luciferase without background fluorescence and bioluminescence. <b>A,</b> Diagram of the NoGlow construct. LoxP-flanked stop site prevents expression of the NoGlow construct in the absence of Cre re ... Full text Cite

FIGURE 1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Tolerance to foreign antigens is animal model specific. <b>A</b> and <b>B,</b> Mice expressing GFP and Luc in the pituitary (GH; <i>n</i> = 5), full-body GFP, and Luc (CAG Luc-GFP; <i>n</i> = ... Full text Cite

FIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. <b>A,</b> WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; <i>n</i> = 5/group) and ser ... Full text Cite

Figure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Validating mutant GFP and Luc activity in Adenovirus vaccines</p> ... Full text Cite

Figure S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Additional E0771 tumor growth in WT, GH, and CAG Luc-GFP mice; MMTV CAG HER2 Ad-HER2 vaccination T cell responses.</p> ... Full text Cite

Movie 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 labelled sidebuds. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p><p></p> ... Full text Cite

Movie 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 invasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 microinvasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>d16HER2 mammary intraepithelial neoplasm. d16HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>d16HER2 labelled sidebuds. d16HER2 shown in yellow. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 microinvasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Supplementary Tables 1-5 for scRNAseq marker genes from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>Supplementary Table 1: Cluster-specific markers from all cells (8,486 cells) Supplementary Table 2: Cluster-specific markers from all epithelial cells (3,843 cells) Supplementary Table 3: Cluster-specific markers from all immune cells (1,8 ... Full text Cite

Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>d16HER2 mammary intraepithelial neoplasm. d16HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 labelled sidebuds. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p><p></p> ... Full text Cite

Data from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <div>Abstract<p>HER2-positive breast cancers are among the most heterogeneous breast cancer subtypes. The early amplification of HER2 and its known oncogenic isoforms provide a plausible mechanism in which distinct programs of tumor het ... Full text Cite

Movie 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 invasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Supplementary Tables 1-5 for scRNAseq marker genes from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>Supplementary Table 1: Cluster-specific markers from all cells (8,486 cells) Supplementary Table 2: Cluster-specific markers from all epithelial cells (3,843 cells) Supplementary Table 3: Cluster-specific markers from all immune cells (1,8 ... Full text Cite

Movie 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>d16HER2 labelled sidebuds. d16HER2 shown in yellow. Krt14 antibody staining shown in green.</p> ... Full text Cite

Data from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <div>Abstract<p>HER2-positive breast cancers are among the most heterogeneous breast cancer subtypes. The early amplification of HER2 and its known oncogenic isoforms provide a plausible mechanism in which distinct programs of tumor het ... Full text Cite

Data from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils

Other · March 31, 2023 <div>Abstract<p>IL26 is a unique amphipathic member of the IL10 family of cytokines that participates in inflammatory signaling through a canonical receptor pathway. It also directly binds DNA to facilitate cellular transduction and int ... Full text Cite

Combined Supplementary Figures from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils

Other · March 31, 2023 <p>SF1: IL-26 protein or mRNA expression in human cell lines and clinical samples; SF2: Single-cell profiling of CD4+ TH17 cells in TNBC patients; SF3: Confirmation of IL-26 knockdown in MDA-MB-231 cells; SF4: In vitro proliferation and in vi ... Full text Cite

Combined Supplementary Figures from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils

Other · March 31, 2023 <p>SF1: IL-26 protein or mRNA expression in human cell lines and clinical samples; SF2: Single-cell profiling of CD4+ TH17 cells in TNBC patients; SF3: Confirmation of IL-26 knockdown in MDA-MB-231 cells; SF4: In vitro proliferation and in vi ... Full text Cite

Figure S4 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

Other · March 31, 2023 <p>Individual histograms of perforin expression by memory CD8 T cell cluster pre- and post-vaccination</p> ... Full text Cite

Table S2 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

Other · March 31, 2023 <p>Concurrent HER2 therapies for each patient for whom CYTOF analysis was done</p> ... Full text Cite

Data from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

Other · March 31, 2023 <div>AbstractPurpose:<p>Immune-based therapy for metastatic breast cancer has had limited success, particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T-cell infiltration of tumors include vaccines ... Full text Cite

Figure S4 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

Other · March 31, 2023 <p>Individual histograms of perforin expression by memory CD8 T cell cluster pre- and post-vaccination</p> ... Full text Cite

Data from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

Other · March 31, 2023 <div>AbstractPurpose:<p>Immune-based therapy for metastatic breast cancer has had limited success, particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T-cell infiltration of tumors include vaccines ... Full text Cite

Table S2 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

Other · March 31, 2023 <p>Concurrent HER2 therapies for each patient for whom CYTOF analysis was done</p> ... Full text Cite

Data from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils

Other · March 31, 2023 <div>Abstract<p>IL26 is a unique amphipathic member of the IL10 family of cytokines that participates in inflammatory signaling through a canonical receptor pathway. It also directly binds DNA to facilitate cellular transduction and int ... Full text Cite

Data from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

Other · March 31, 2023 <div>AbstractPurpose:<p>Despite promising advances in breast cancer immunotherapy, augmenting T-cell infiltration has remained a significant challenge. Although neither individual vaccines nor immune checkpoint blockade (ICB) have had b ... Full text Cite

Data from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

Other · March 31, 2023 <div>AbstractPurpose:<p>Despite promising advances in breast cancer immunotherapy, augmenting T-cell infiltration has remained a significant challenge. Although neither individual vaccines nor immune checkpoint blockade (ICB) have had b ... Full text Cite

Immunotherapy of surgical malignancies: Commentary

Other Diseases of the Colon and Rectum · January 1, 2005 Cite

Tackling T-cell tumors

Other Blood · October 1, 2003 Full text Cite

Surrogate markers of response to cancer immunotherapy.

Other Expert Opin Biol Ther · March 2001 Clinically effective cancer immunotherapy has been sought for more than 100 years and has been recently applied most successfully in strategies that passively deliver immune effectors such as monoclonal antibodies (anti-CD20 for lymphoma and anti-HER2/neu ... Full text Link to item Cite

Gene therapy in surgery.

Other Ann Surg · February 1996 Full text Link to item Cite

UNTITLED

Other ANNALS OF SURGERY · February 1, 1995 Link to item Cite

Transmissible agents and the surgeon.

Other J Am Coll Surg · January 1995 Link to item Cite

Survey: Invited commentary (I)

Other Archives of Surgery · January 1, 1990 Cite

Prospects for development of a vaccine against HIV-related disorders

Other Clinical Immunology Newsletter · January 1, 1987 Full text Cite